Experienced in Febrile Neutropenia

Dr. Keri R. Maher

Oncology | Hematology
Mcv Associated Physicians
1001 E Leigh St, 
Richmond, VA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
14 Years of Experience
Experienced in Febrile Neutropenia
Mcv Associated Physicians
1001 E Leigh St, 
Richmond, VA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Keri Maher is an Oncologist and a Hematologist in Richmond, Virginia. Dr. Maher has been practicing medicine for over 14 years and is rated as an Experienced provider by MediFind in the treatment of Febrile Neutropenia. Her top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Childhood Acute Myeloid Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Maher is currently accepting new patients.

Her clinical research consists of co-authoring 14 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Licenses
Student in an Organized Health Care Education/Training Program in AZ
Hospital Affiliations
Medical College Of Virginia Hospitals
Vcu Health Tappahannock Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
HealthKeepers
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Piedmont
  • HMO
  • POS
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

MCV ASSOCIATED PHYSICIANS
1001 E Leigh St, Richmond, VA 23298

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)
A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)
Enrollment Status: Recruiting
Publish Date: August 15, 2025
Intervention Type: Procedure, Drug
Study Drug: AKR1C3-Activated Prodrug OBI-3424
Study Phase: Phase 1/Phase 2
A Phase 2, Randomized, Open-Label, Multicenter Study to Evaluate Safety and Efficacy of Single Agent Selinexor Versus Treatment of Physician's Choice in Patients With Previously Treated Myelofibrosis
A Phase 2, Randomized, Open-Label, Multicenter Study to Evaluate Safety and Efficacy of Single Agent Selinexor Versus Treatment of Physician's Choice in Patients With Previously Treated Myelofibrosis
Enrollment Status: Active_not_recruiting
Publish Date: October 03, 2025
Intervention Type: Drug, Other
Study Drug: Selinexor
Study Phase: Phase 2
A Phase 1/3 Study to Evaluate Efficacy and Safety of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Ruxolitinib in Treatment-naïve Patients With Myelofibrosis
A Phase 1/3 Study to Evaluate Efficacy and Safety of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Ruxolitinib in Treatment-naïve Patients With Myelofibrosis
Enrollment Status: Active_not_recruiting
Publish Date: October 03, 2025
Intervention Type: Other, Drug
Study Drugs: Selinexor, Ruxolitinib
Study Phase: Phase 3
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Enrollment Status: Active_not_recruiting
Publish Date: September 30, 2025
Intervention Type: Drug, Other, Procedure
Study Drugs: Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Melphalan
Study Phase: Phase 3
A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease
A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease
Enrollment Status: Suspended
Publish Date: September 22, 2025
Intervention Type: Biological
Study Drugs: Blinatumomab, Inotuzumab
Study Phase: Phase 2
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
Enrollment Status: Suspended
Publish Date: September 05, 2025
Intervention Type: Biological, Drug, Procedure, Other
Study Drugs: Allopurinol, Cytarabine, Daunorubicin Hydrochloride, Vincristine Sulfate, Dexamethasone, Pegylated L-Asparaginase, Methotrexate, Cyclophosphamide, Mercaptopurine, Rituximab, Doxorubicin, Thioguanine, Inotuzumab
Study Phase: Phase 3
Phase 1B/II Study of Escalating Doses of Pevonedistat (TAK-924, Formerly MLN4924) Administered in Combination With Standard Induction Chemotherapy (Cytarabine and Idarubicin) in Newly Diagnosed High Risk Acute Myelogenous Leukemia (AML)
Phase 1B/II Study of Escalating Doses of Pevonedistat (TAK-924, Formerly MLN4924) Administered in Combination With Standard Induction Chemotherapy (Cytarabine and Idarubicin) in Newly Diagnosed High Risk Acute Myelogenous Leukemia (AML)
Enrollment Status: Active_not_recruiting
Publish Date: June 11, 2025
Intervention Type: Drug, Other
Study Drugs: Cytarabine, Idarubicin, Pevonedistat
Study Phase: Phase 1/Phase 2
A Phase 1 Study of MLN4924 (Pevonedistat) and Belinostat in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
A Phase 1 Study of MLN4924 (Pevonedistat) and Belinostat in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Enrollment Status: Terminated
Publish Date: June 04, 2025
Intervention Type: Drug
Study Drugs: Belinostat, Pevonedistat
Study Phase: Phase 1
GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Enrollment Status: Terminated
Publish Date: January 27, 2025
Intervention Type: Drug
Study Drugs: Itacitinib, Methylprednisolone, Prednisone
Study Phase: Phase 2/Phase 3
A Randomized Phase II/III Trial of Novel Therapeutics Versus Azacitidine in Newly Diagnosed Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older LEAP: Less-Intense AML Platform Trial
A Randomized Phase II/III Trial of Novel Therapeutics Versus Azacitidine in Newly Diagnosed Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older LEAP: Less-Intense AML Platform Trial
Enrollment Status: Completed
Publish Date: January 16, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Azacitidine, Cytarabine, Decitabine, Midostaurin, Nivolumab
Study Phase: Phase 2/Phase 3
Phase I Study of Inotuzumab Ozogamicin With 3 and 4 Drug Augmented Berlin-Frankfurt-Münster (BFM) Re-Induction for Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL)
Phase I Study of Inotuzumab Ozogamicin With 3 and 4 Drug Augmented Berlin-Frankfurt-Münster (BFM) Re-Induction for Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL)
Enrollment Status: Active_not_recruiting
Publish Date: August 22, 2023
Intervention Type: Drug
Study Drugs: Inotuzumab ozogamicin, Prednisone, Daunorubicin, Vincristine, Cytarabine, Methotrexate, Pegaspargase
Study Phase: Phase 1
A Phase Ia/b Dose Escalation and Expansion, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of APTO-253 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplasia
A Phase Ia/b Dose Escalation and Expansion, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of APTO-253 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplasia
Enrollment Status: Terminated
Publish Date: August 22, 2022
Intervention Type: Drug
Study Drug: APTO-253
Study Phase: Phase 1
View 11 Less Clinical Trials

14 Total Publications

Selinexor plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis: SENTRY Phase 3 study design.
Selinexor plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis: SENTRY Phase 3 study design.
Journal: Future oncology (London, England)
Published: February 06, 2025
Similar Doctors
Advanced in Febrile Neutropenia
Dr. Yogesh K. Gandhi
Hematology Oncology | Hematology | Oncology
Advanced in Febrile Neutropenia
Dr. Yogesh K. Gandhi
Hematology Oncology | Hematology | Oncology

Virginia Cancer Institute Incorporated

1401 Johnston Willis Dr, Suite 100, 
North Chesterfield, VA 
 (8.0 miles away)
804-330-7990
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Yogesh Gandhi is a Hematologist Oncology specialist and a Hematologist in North Chesterfield, Virginia. Dr. Gandhi is rated as a Distinguished provider by MediFind in the treatment of Febrile Neutropenia. His top areas of expertise are Thrombocytopenia, Pleuropulmonary Blastoma, Lung Cancer, and Familial Colorectal Cancer. Dr. Gandhi is currently accepting new patients.

Advanced in Febrile Neutropenia
Dr. Elke K. Friedman
Hematology Oncology | Hematology | Oncology
Advanced in Febrile Neutropenia
Dr. Elke K. Friedman
Hematology Oncology | Hematology | Oncology

Virginia Cancer Institute Incorporated

1401 Johnston Willis Dr, Suite 100, 
North Chesterfield, VA 
 (8.0 miles away)
804-330-7990
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Elke Friedman is a Hematologist Oncology specialist and a Hematologist in North Chesterfield, Virginia. Dr. Friedman is rated as a Distinguished provider by MediFind in the treatment of Febrile Neutropenia. Her top areas of expertise are Breast Cancer, Lung Cancer, Paget Disease of the Breast, Bone Marrow Aspiration, and Endoscopy. Dr. Friedman is currently accepting new patients.

Advanced in Febrile Neutropenia
Dr. James L. Khatcheressian
Hematology Oncology | Oncology
Advanced in Febrile Neutropenia
Dr. James L. Khatcheressian
Hematology Oncology | Oncology

Virginia Cancer Institute Incorporated

1401 Johnston Willis Dr, Suite 100, 
North Chesterfield, VA 
 (8.0 miles away)
804-330-7990
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

James Khatcheressian is a Hematologist Oncology specialist and an Oncologist in North Chesterfield, Virginia. Dr. Khatcheressian is rated as a Distinguished provider by MediFind in the treatment of Febrile Neutropenia. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Inflammatory Breast Cancer. Dr. Khatcheressian is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Maher's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 51 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile